Share
516 Posts.
lightbulb Created with Sketch. 1671
clock Created with Sketch. 02/04/25
20:32
Share
Originally posted by ashgood123:
↑
UBS really loves Telix. It's down ~15% from the peak and they are already out there selling it like it's halved. The analysts, after speaking to pharma experts, are of the opinion no such approval bottlenecking will happen, and thus see the sell-off as a buying opportunity for Aussie stocks, particularly Telix (ASX:TLX) which has dipped approximately 8.5 per cent lower since Mr Marks resigned.“We remain high-conviction buyers of Telix,” the note reads. “The shares are trading down … despite incrementally positive news … All else equal, this sort of share price response indicates strong propensity to move with sentiment on US biotech rather than Australian biotech where the tape currently looks mixed for the day. We view this as a buying opportunity given Telix is profitable and has a string of catalysts in the coming months, most of which we think constitute upside risk.”
Expand
Hmmm, so UBS sees Telix as a great buy because they're profitable - with a PE of 177. Neuren, on the other hand, also profitable, but with a PE of 9.7, is a clear sell. What am I missing here.
(20min delay)